Table 1.
Clinical information for the nine women from the CAPRISA 002 cohort
| Participant ID | Drug regimen* | Time ART naïve (weeks) | Time on ART (weeks) | CD4 count at ART initiation (cells/μl) | CD4 count at QVOA blood draw (cells/μl) | Number of outgrowth viruses | Percent clonal outgrowth viruses | Percent outgrowth viruses from 1 year pre-ART | Percent Outgrowth viruses from within one year of transmission** |
|---|---|---|---|---|---|---|---|---|---|
| CAP188 | EFV/3TC/TDF EFV/FTC/TDF |
247 | 246 | 364 | 430 | 12 | 0 | 50 | 0 |
| CAP206 | EFV/3TC/TDF EFV/FTC/TDF |
274 | 286 | 289 | 978 | 21 | 19 | 78 | 5 |
| CAP217 | EFV/3TC/TDF | 360 | 239 | 287 | 657 | 17 | 12 | 44 | 0 |
| CAP257 | 3TC/NVP/TDF EFV/3TC/TDF EFV/FTC/TDF |
249 | 318 | 170 | 596 | 48 | 17 | 89 | 0 |
| CAP287 | EFV/FTC/TDF | 260 | 223 | 411 | 559 | 6 | 0 | 67 | 17 |
| CAP288 | EFV/FTC/TDF | 210 | 275 | 318 | 860 | 7 | 0 | 100 | 0 |
| CAP302 | EFV/3TC/AZT EFV/3TC/AZT EFV/FTC/TDF |
164 | 270 | 307 | 541 | 8 | 38 | 17 | 17 |
| CAP316 | 3TC/AZT/LPV/r EFV/FTC/TDF |
215 | 215 | 436 | 888 | 11 | 0 | 91 | 0 |
| CAP336 | EFV/3TC/TDF | 142 | 258 | 164 | 558 | 17 | 47 | 100 | 0 |
| Average = | 236 | 259 | 305 | 674 | 16 | 15 | 71 | 4 | |
| Median = | 247 | 258 | 307 | 596 | 12 | 12 | 78 | 0 | |
EFV = Efavirenz, 3TC = Lamivudine, TDF = Tenofovir, NVP = Nevirapine, AZT = Zidovudine, LPV/r = Lopinavir/Ritonavir,
FTC = Emtricitabine
ART = antiretroviral therapy; QVOA = quantitative virus outgrowth assay
*
Regimen changes indicated below original/prior regimen
**
Acute/early infection here refers to sampling time points in the first year of study enrolment